|Bid||0.00 x 1100|
|Ask||0.00 x 1000|
|Day's range||7.99 - 8.24|
|52-week range||4.00 - 10.23|
|Beta (5Y monthly)||0.97|
|PE ratio (TTM)||N/A|
|Earnings date||07 Aug 2023 - 11 Aug 2023|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||10 Nov 2010|
|1y target est||13.10|
Bausch (BHC) obtains a positive ruling for one of its top drugs, Xifaxan, against Norwich from the U.S. District Court of Delaware. Stock up in response to the same.
The simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by...
Shares of Bausch Health (NYSE: BHC) were up more than 27% late Wednesday afternoon because the company announced it had received a favorable court ruling affecting one of its leading therapies. The healthcare company announced that the U.S. District Court of Delaware had ruled in its favor in a lawsuit by Bausch wholly owned subsidiary Salix Pharmaceuticals against Norwich Pharmaceuticals.
Bausch (BHC) declines as it misses on earnings and sales in the first quarter.
The headline numbers for Bausch (BHC) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Bausch (BHC) delivered earnings and revenue surprises of -30.67% and 0.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Bausch + Lomb (BLCO) delivered earnings and revenue surprises of -28.57% and 3.98%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
With a price-to-sales (or "P/S") ratio of 0.3x Bausch Health Companies Inc. ( NYSE:BHC ) may be sending very bullish...
With a price-to-sales (or "P/S") ratio of 1.5x Bausch + Lomb Corporation ( NYSE:BLCO ) may be sending very bullish...
Investors need to pay close attention to Bausch Health (BHC) stock based on the movements in the options market lately.
With the business potentially at an important milestone, we thought we'd take a closer look at Bausch Health Companies...
Bausch (BHC) delivered earnings and revenue surprises of 10.87% and 3.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Perion Network and West Fraser Timber are part of the Zacks Bull and Bear of the Day article.
Bausch + Lomb ( NYSE:BLCO ) Full Year 2022 Results Key Financial Results Revenue: US$3.77b (flat on FY 2021). Net...
Let us look at four drug and biotech companies, MRNA, BHC, ALNY and AGIO, which are gearing up for their earnings release.
A look at the shareholders of Bausch Health Companies Inc. ( NYSE:BHC ) can tell us which group is most powerful. With...
Bausch (BHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Bausch + Lomb's (NYSE:BLCO) stock is up by a considerable 12% over the past three months. But the company's key...
It's nice to see the Bausch Health Companies Inc. ( NYSE:BHC ) share price up 19% in a week. But the last three years...
Investors need to pay close attention to Bausch + Lomb (BLCO) stock based on the movements in the options market lately.
ACCO, BHC and HOUS have been added to the Zacks Rank #5 (Strong Sell) List on December 9, 2022.
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") has designated 1261229 B.C. Ltd., the entity that directly or indirectly holds 88.7% of the issued and outstanding shares of Bausch + Lomb Corporation ("Bausch + Lomb"), as an unrestricted subsidiary of the Company in accordance with the terms of the Company's debt documents. In connection therewith, all of the subsidiaries of 1261229 B.C.
How far off is Bausch + Lomb Corporation ( NYSE:BLCO ) from its intrinsic value? Using the most recent financial data...
Bausch Health Companies ( NYSE:BHC ) Third Quarter 2022 Results Key Financial Results Revenue: US$2.05b (down 3.1% from...